UNLIMITED TURBO BULL - NOVO-NORDISK B | Market Closed - Euronext Paris 17:30:00 16/05/2024 BST | ||
| 6.54 EUR | -0.46% |
|
| Current month | +4.31% | ||
| 1 month | +9.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 16/05/24 | 6.54 | -0.46% |
| 15/05/24 | 6.57 | +0.77% |
| 14/05/24 | 6.52 | +1.09% |
| 13/05/24 | 6.45 | +3.70% |
| 10/05/24 | 6.22 | +0.81% |
Real-time Euronext Paris
Last update May 16, 2024 at 05:30 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| 8P24S | |
| ISIN | DE000SQ825U9 |
| Date issued | 14/02/2023 |
| Strike | 428.3 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.26 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.08 € |
|---|---|
| Lowest since issue | 1.065 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
912.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.40%
- Stock Market
- Certificates
- 8P24S Certificat
